DIY Human IFN-Lambda 1/2/3 (IL-29/28A/28B) ELISA (TCM)
Catalog Number: 61840
This DIY ELISA kit is designed to detect human IFN-Lambda 1, 2, and 3 (IL-29, 28A, and B). This kit is most reactive with Lambda 3 and Lambda 1. The standard in this kit is IFNL1 and IFNL3 (IL-29, IL-28B).
$730.00
Product Info
| Matrix Compatibility | Tissue Culture Media (TCM) |
|---|---|
| Assay Range | 62.5 - 4000 pg/ml |
| Assay Length | 4 hours, 40 minutes |
| Specificity | Human Interferon Lambda 3 (IL-28B) and Human Interferon Lambda 2 (IL-28A) |
This DIY ELISA is a Do-It-Yourself Development kit that contains the basic components necessary for the development of sandwich ELISAs to measure natural and recombinant Human Interleukin-29 (IL-29), Human Interleukin-28A (IL-28A), and Human Interleukin-28B (IL-28B). DIY kits are intended for the analysis of cell culture supernates. Other matrices need to be evaluated on a case-by-case basis. When used according to instructions and recommended materials, each DIY kit contains sufficient materials to develop approximately fifteen 96-well ELISA plates.
Specifications
| Cross-reactivity |
No cross-reactivity against
|
|---|---|
| Synonyms | Mouse Beta Interferon, Mouse IFN Beta, Mouse Type I IFN beta, Mouse Fibroblast IFN, Mouse Fibroblast Interferon, Mouse Beta IFN, Mouse Type I Interferon Beta |
| Storage | 2-8°C for short term storage; -20°C/-70°C for long term storage |
| Expiration Date | 6 months from the date of manufacture |
| Shipping Condition | Wet Ice |
Materials Provided
- Capture Antibody
- Detection Antibody
- Standard
- Streptavidin-HRP
Solutions Required (Not Provided)
- PBS
- Wash Buffer
- Reagent Diluent
- Substrate Solution
- Stop Solution
Tech Info & Data
Background
IL-28A, IL-28B and IL-29 are a recently discovered class II cytokine family that displays similar properties to type I interferons (IFNs)1,2. Similarly, they have been shown to function by signaling through the JAK-STAT pathway, upregulating the expression of genes involved in controlling viral replication and cellular proliferation. Consequently, they have also been described in the literature as lambda IFNs (IFN-λ1[IL29], IFN-λ2 [IL-28A] and IFN-λ3 [IL-28B]) or collectively as type III IFNs. Additional studies have shown that both type I and type III IFNs are upregulated during viral infection, suggesting each may have similar and perhaps distinct roles in controlling the host response to pathogens3. All type III IFNs signal through a heterodimer receptor complex comprised of the IL-10R2 and the IL-28αR receptor chains to initiate the signal transduction cascade. In contrast, all the type I IFNs (α, β, ε, κ, ω) initiate signaling by binding to the IFNAR1/ IFNAR2 receptor complex to promote signaling. IFNAR gene knockout studies have indicated that type III IFNs cannot effectively maintain a potent antiviral response. In contrast, IL28αR knockouts showed little effect on the overall antiviral response, suggesting that the role of type III interferons may be more selective to specific cells and viruses. However, either receptor knockout showed a strong reduction in reducing viral load when mice were treated with TLR3 and TLR9 agonists4. Therefore, it may be possible that the type III IFNs have been evolutionarily conserved to combat pathogens that target specifically the IFNAR receptor complex or other unique aspects of the classical type I IFN pathways5.
Citations
3 Citations:
- Oon, Shereen, et al. (2016). A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus. JCI Insight, 15 pgs. PMID: 27699260. (link)
- Soederholm, Sandra, et al. (2016). Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine. Antiviral Research, 12 pgs. PMID: 26738783. (link)
- Schmid, Bianca, et al. (2015). Live Cell Analysis and Mathematical Modeling Identify Determinants of Attenuation of Dengue Virus 2’-O- Methylation Mutant. PLOS Pathogens, 36 pgs. PMID: 26720415. (link)
References:
- Sheppard et al. (2003) Nat. Immunol. 4:63-68.
- Kotenko et al. (2007) Nat. Immunol. 4:69-77.
- Onoguchi et al. (2007) J. Immunol. 282:7576-7581.
- Ank et al. (2008) J. Immunol. 180:2474-2485.
- Ank et al. (2006) JICR. 26:373-379.